Financial Performance (Q1 FY27 vs. Q1 FY26)

  • Revenue from operations: Declined 12% from ₹691 crore to ₹612 crore year-on-year
  • Gross profit: Decreased 4% from ₹202 crore to ₹193.16 crore
  • Gross profit margin: Improved from 29% to 31.6%
  • EBITDA: Declined approximately 20% year-on-year
  • EBITDA margin: Reduced from 12.2% to 11.1%
  • PAT margin: Reduced from 8.4% to 7.2%
  • Volume decline: Approximately 13% year-on-year
  • Price increase: Approximately 2% year-on-year

Business Segment Performance (Q1 FY27)

  • B2C sales: 64% of total revenue (vs. 75% in Q1 FY26)
  • B2B sales: 34% of total revenue (vs. 23% in Q1 FY26)
  • Export sales: 2% of total revenue (same as Q1 FY26)
  • Product category mix within B2C: Insecticides 33%, Herbicides 59%, Fungicides 5%, PGR 3%

Premium Product Performance

  • Premium product contribution: Increased to 64% of B2C sales from 58% in Q1 FY26
  • Focus Maharatna products: Target to reach 70% contribution in next 3-4 years

New Product Launches

  • Granuvia and Spinoace: Launched in collaboration with Corteva Agriscience
  • Q1 FY27 sales from these new products: ₹5.50 crore
  • Previous year's launched products: Sales increased from ₹1.67 crore (Q1 FY26) to ₹2.29 crore (Q1 FY27)
  • Revenue from in-licensing products: Increased from ₹36 crore (Q1 FY26) to ₹46 crore (Q1 FY27)
  • Revenue from patented products: Decreased from ₹97 crore to ₹70 crore, mainly due to reduction in Hachiman sales
  • Contribution from combination products: Decreased from ₹134 crore to ₹98 crore

Operational Highlights

Farmer Engagement Activities (Q1 FY27):

  • 3,600+ farmer meetings conducted
  • 600 field days organized
  • 1,400 demonstrations conducted
  • 15,000+ farmer visits made
  • Supported by 8,500+ distributors and 70,000 retail network

IIL Crop Solutions Program:

  • Currently 36 plots operational
  • Planning to double number of plots
  • Expanding to 14 states and 4 crops (rice, cotton, chili, soybean)

KAEROS Research:

  • More than 40 products already commercialized
  • Focus on scaling into meaningful second growth platform
  • Target CAGR of 100% initially, then 50-60%
  • Current margins in single digits

International Business:

  • Registrations, partnerships and customer opportunities developing across Latin America, Europe, ASEAN
  • Technicals sales gaining acceptance
  • White labeling business developing

Manufacturing and Capacity Expansion

Dahej Facility:

  • Providing additional capability and flexibility
  • More than 70% commercialized, another 20-30% to be commercialized soon
  • Potential to add ₹200 crore in technical production
  • Herbicide and insecticide plants being separated

Sotanala Project:

  • Total investment: Approximately ₹200 crore (₹50 crore formulations, ₹150 crore technical)
  • Investment made so far: Approximately ₹70 crore
  • Formulation facility: Expected commencement April-May 2027
  • Technical production: Expected by Diwali 2027 (subject to project schedule)
  • First phase: 5-6 products identified for transfer from Chopanki
  • TCS plant: Fully automatic plant

Other Facilities:

  • Chopanki: Handling new AI (Active Ingredients)
  • Udhampur: Investments differentiating between herbicide and insecticide plants, completion expected within current year

Raw Material and Cost Environment

  • Crude and petroleum-linked raw material costs remained area of pressure
  • Solvent prices fluctuating 25-30% week-to-week
  • Plastic prices (HDPE), emulsifiers also highly fluctuating
  • Company addressing through calibrated pricing, better product mix, and increasing contribution from differentiated products

Working Capital and Capital Allocation

  • June inventory slightly elevated due to slower start of agricultural season
  • Focus on improving inventory turns, collections, and alignment between placement and underlying demand
  • Objective to reduce working capital cycle as season normalizes
  • Annual capex expected to normalize around ₹30-40 crores (maintenance capex) after current projects completed
  • Focus on utilization, cash generation and returns improvement

Outlook and Guidance

  • Agriculture cycle largely deferred rather than lost
  • Expect stronger execution over remaining three quarters
  • Positive impact expected from Q2 onwards
  • Focus on converting opportunities from product launches, farmer engagement, KAEROS, international business
  • Operating leverage and efficiency initiatives expected to support ROCE and ROE improvement from Q3 onwards (September-October)
  • Efficiency initiatives include renewable energy, lower electricity and fuel consumption, AI implementation

Q&A Highlights

Capacity Utilization: Company aims to double business in 4-5 years through product mix improvement, technical manufacturing enhancement, and international business development.

Price Hikes: Attempted hikes in March, April, and May but some rollbacks due to weak market sentiment. Strategic cost increases were implemented but extraordinary hikes could not be taken.

Margin Structure: Focus Maharatna products at 35%+ margins, Maharatna at 30%+ margins, generics at 10-15% margins.

Sales Returns: Expecting sales returns to be reduced to at least half of previous year's ₹200 crore due to cautious placement strategy and product variety focus.

New Product Expectations: Granuvia expected to reach ₹20 crore, Spinoace ₹10 crore+ in FY27, totaling ₹30-35 crore gross sales (~₹25 crore net).

Buyback Plans: Company typically does buyback every 2-3 years, decision to be made after quarter completion.

#Tags: #InsecticidesIndia #Q1Results #Agrochemicals #SEBIDisclosure #EarningsCall #Neutral